AGP Executive Report
Last update: 8 hours agoEU Health Policy: The European Commission approved MSD’s Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with the first PD-1 inhibitor + antibody-drug conjugate option for this group across EU states plus Iceland, Liechtenstein and Norway. EU Justice & Security: Brussels proposed stronger EU-wide mandates for Europol and Eurojust, updates to the European Investigation Order, and changes to data rules for Union bodies to speed cross-border serious-crime and terrorism cases. Liechtenstein in the Regulatory Spotlight: Bitcoin Suisse secured a MiCAR Crypto Asset Service Provider licence in Liechtenstein, giving it a regulated route to expand services across selected EEA markets. Cross-Border Migration Debate (Switzerland): A Swiss parliamentary push would add “security” and “infrastructure” style fees for foreign residents, raising free-movement concerns for EU/EFTA nationals including Liechtenstein citizens. Public Safety: Switzerland raised heatwave warnings to level 4 across large areas, including parts of the Rhine Valley and Ticino.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
